Humasis Co. Ltd (205470) - Total Liabilities
Based on the latest financial reports, Humasis Co. Ltd (205470) has total liabilities worth ₩90.75 Billion KRW (≈ $61.50 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore 205470 shareholders equity momentum to track the company's year-over-year net asset growth rate.
Humasis Co. Ltd - Total Liabilities Trend (2014–2024)
This chart illustrates how Humasis Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. See 205470 cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
Humasis Co. Ltd Competitors by Total Liabilities
The table below lists competitors of Humasis Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Formuepleje Limittellus
CO:FPILIM
|
Denmark | Dkr2.00K |
|
VIROMED MEDICAL NA O.N.
XETRA:VME
|
Germany | €3.44 Million |
|
Doktas Dokumculuk Ticaret ve Sanayi AS
IS:DOKTA
|
Turkey | TL13.08 Billion |
|
Caisse Regionale De Credit Agricole Mutuel Sud Rhone Alpes
PA:CRSU
|
France | €24.15 Billion |
|
Alcatel Lucent Teletas Telekomunikasyon AS
IS:ALCTL
|
Turkey | TL2.29 Billion |
|
Ram Essential Services Property Fund
AU:REP
|
Australia | AU$292.55 Million |
|
Vizsla Royalties Corp.
V:VROY
|
Canada | CA$499.70K |
Liability Composition Analysis (2014–2024)
This chart breaks down Humasis Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Humasis Co. Ltd (205470) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.49 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.41 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.27 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Humasis Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Humasis Co. Ltd (2014–2024)
The table below shows the annual total liabilities of Humasis Co. Ltd from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩102.65 Billion ≈ $69.57 Million |
+71.14% |
| 2023-12-31 | ₩59.98 Billion ≈ $40.65 Million |
-50.35% |
| 2022-12-31 | ₩120.80 Billion ≈ $81.86 Million |
-12.91% |
| 2021-12-31 | ₩138.71 Billion ≈ $94.00 Million |
+611.03% |
| 2020-12-31 | ₩19.51 Billion ≈ $13.22 Million |
-8.17% |
| 2019-12-31 | ₩21.24 Billion ≈ $14.40 Million |
+16.93% |
| 2018-12-31 | ₩18.17 Billion ≈ $12.31 Million |
+42.74% |
| 2017-12-31 | ₩12.73 Billion ≈ $8.63 Million |
+906.96% |
| 2016-12-31 | ₩1.26 Billion ≈ $856.63K |
-70.13% |
| 2015-12-31 | ₩4.23 Billion ≈ $2.87 Million |
+1.78% |
| 2014-12-31 | ₩4.16 Billion ≈ $2.82 Million |
-- |
About Humasis Co. Ltd
Humasis Co. Ltd. manufactures and sells pharmaceuticals and medical devices in South Korea and internationally. It offers immunodiagnostic kits, such as quantitative and qualitative tests, cardiac and cancer markers, infectious diseases, hormones, and women's health. The company also provides bio-material products, such as COVID-19 nucleocapsid protein, human immunodeficiency virus surface protei… Read more